Showing results (2051-2060 of 2,210) with videos related to
Sort By:
Pageof 221
Nature|May 8, 1997
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionT W Chun, L Carruth, D Finzi, et al.Methodsx|October 4, 2022
A detailed manual segmentation procedure for the hypothalamus for 3T T1-weighted MRIMohammad Ali, Jee Su Suh, Milita Ramonas, et al.Neuroimage. Clinical|October 28, 2021
Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND reportPedro L Ballester, Jee Su Suh, Nikita Nogovitsyn, et al.Endocrine-Related Cancer|June 3, 2024
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapyMarcia S Brose, Jaume Capdevila, Rossella Elisei, et al.Journal of Affective Disorders|February 19, 2026
Lam Employment Absence and Productivity Scale (LEAPS): Analysis of the minimal clinically important difference (MCID) in patients with major depressive disorder using data from the CAN-BIND-1 studyShiny Sachdeva, Victor W Li, Trisha Chakrabarty, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 22, 1999
Antibodies against the first Ig-like domain of human platelet endothelial cell adhesion molecule-1 (PECAM-1) that inhibit PECAM-1-dependent homophilic adhesion block in vivo neutrophil recruitmentM T Nakada, K Amin, M Christofidou-Solomidou, et al.Science Advances|May 31, 2023
An AAV-CRISPR/Cas9 strategy for gene editing across divergent rodent species: Targeting neural oxytocin receptors as a proof of conceptArjen J Boender, Marina Boon, H Elliott Albers, et al.American Heart Journal|December 3, 2014
The palliative care in heart failure trial: rationale and designRobert J Mentz, James A Tulsky, Bradi B Granger, et al.The Journal of Clinical Endocrinology and Metabolism|October 19, 2021
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid CancerMarcia S Brose, Yury Panaseykin, Bhavana Konda, et al.The Lancet. Haematology|October 10, 2021
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 studyChristiane Querfeld, John A Thompson, Matthew H Taylor, et al.Pageof 221